Abstract
In March 2011, ipilimumab (Yervoy; Bristol-Myers Squibb), a human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA4), was approved by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications
Cancer and Metastasis Reviews Open Access 03 August 2022
-
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Cell Communication and Signaling Open Access 07 April 2022
-
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Cancer Cell International Open Access 03 January 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).
Salama, A. K. & Hodi, F. S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 5 Apr 2011 (doi: clincanres.2232.2011).
Leach, D. R. et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).
US FDA. FDA labeling information — Yervoy. FDA website [online], (2011).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).
Tong, M. et al. Wells Fargo Securities, equity research. (28 March 2011).
Holfrod, J. et al. Jefferies company note, Bristol-Myers Squibb. (31 March 2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sondak, V., Smalley, K., Kudchadkar, R. et al. Ipilimumab. Nat Rev Drug Discov 10, 411–412 (2011). https://doi.org/10.1038/nrd3463
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3463
This article is cited by
-
Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
Medicinal Chemistry Research (2023)
-
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Cell Communication and Signaling (2022)
-
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Cancer Cell International (2022)
-
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications
Cancer and Metastasis Reviews (2022)
-
A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy
Biomaterials Research (2018)
